The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Phase 2b Controlled Trial of M72/AS01 E Vaccine to Prevent Tuberculosis
Open accessAbstract
BACKGROUNDA vaccine to interrupt the transmission of tuberculosis is needed. METHODSWe conducted a randomized, double-blind, placebo-controlled, phase 2b trial of the M72/AS01 E tuberculosis vaccine in Kenya, South Africa, and Zambia.Human immunodeficiency virus (HIV)-negative adults 18 to 50 years of age with latent M. tuberculosis infection (by interferon-γ release assay) were randomly assigned (in a 1:1 ratio) to receive two doses of either M72/AS01 E or placebo intramuscularly 1 month apart.Most participants had previously received the bacille Calmette-Guérin vaccine.We assessed the safety of M72/AS01 E and its efficacy against progression to bacteriologically confirmed active pulmonary tuberculosis disease.Clinical suspicion of tuberculosis was confirmed with sputum by means of a polymerase-chain-reaction test, mycobacterial culture, or both. RESULTSWe report the primary analysis (conducted after a mean of 2.3 years of follow-up) of the ongoing trial.A total of 1786 participants received M72/AS01 E and 1787 received placebo, and 1623 and 1660 participants in the respective groups were included in the according-to-protocol efficacy cohort.A total of 10 participants in the M72/AS01 E group met the primary case definition (bacteriologically confirmed active pulmonary tuberculosis, with confirmation before treatment), as compared with 22 participants in the placebo group (incidence, 0.3 cases vs. 0.6 cases per 100 person-years).The vaccine efficacy was 54.0% (90% confidence interval [CI], 13.9 to 75.4; 95% CI, 2.9 to 78.2; P = 0.04).Results for the total vaccinated efficacy cohort were similar (vaccine efficacy, 57.0%; 90% CI, 19.9 to 76.9; 95% CI, 9.7 to 79.5; P = 0.03).There were more unsolicited reports of adverse events in the M72/ AS01 E group (67.4%) than in the placebo group (45.4%) within 30 days after injection, with the difference attributed mainly to injection-site reactions and influenzalike symptoms.Serious adverse events, potential immune-mediated diseases, and deaths occurred with similar frequencies in the two groups. CONCLUSIONSM72/AS01 E provided 54.0% protection for M. tuberculosis-infected adults against active pulmonary tuberculosis disease, without evident safety concerns.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling
Houben, R. M. G. J., & Dodd, P. J. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1002152 · Cited by 2,054
Tameris, M. D., Hatherill, M., Landry, B. S., Scriba, T. J., Snowden, M. A., Lockhart, S., Shea, J. E., McClain, J. B., Hussey, G. D., Hanekom, W. A., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60177-4 · Cited by 1,049
Self-citationProtection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials
Mangtani, P., Abubakar, I., Ariti, C., Beynon, R., Pimpin, L., Fine, P. E. M., Rodrigues, L. C., Smith, P. G., Lipman, M., Whiting, P. F., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/cit790 · Cited by 995
Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli
Behr, M., Warren, S., Salamon, H., Hopewell, P., de Leon, A. P., Daley, C., & Small, P. (1999) · The Lancet · doi:10.1016/s0140-6736(98)03406-0 · Cited by 754
Dheda, K., Gumbo, T., Maartens, G., Dooley, K. E., McNerney, R., Murray, M., Furin, J., Nardell, E. A., London, L., Lessem, E., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30079-6 · Cited by 684
Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination
Nemes, E., Geldenhuys, H., Rozot, V., Rutkowski, K. T., Ratangee, F., Bilek, N., Mabwe, S., Makhethe, L., Erasmus, M., Toefy, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714021 · Cited by 652
Self-citationCadena, A. M., Fortune, S. M., & Flynn, J. L. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.69 · Cited by 484
Skeiky, Y. A. W., Alderson, M. R., Ovendale, P. J., Guderian, J. A., Brandt, L., Dillon, D. C., Campos-Neto, A., Lobet, Y., Dalemans, W., Orme, I. M., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.12.7618 · Cited by 313
von Reyn, C. F., Mtei, L., Arbeit, R. D., Waddell, R., Cole, B., Mackenzie, T., Matee, M., Bakari, M., Tvaroha, S., Adams, L. V., et al. (2010) · AIDS · doi:10.1097/qad.0b013e3283350f1b · Cited by 220
Cited by
Vaccine adjuvants: mechanisms and platforms
Zhao, T., Cai, Y., Jiang, Y., He, X., Wei, Y., Yu, Y., & Tian, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01557-7 · Cited by 1,020
Furin, J., Cox, H., & Pai, M. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30308-3 · Cited by 873
Final Analysis of a Trial of M72/AS01 E Vaccine to Prevent Tuberculosis
Tait, D. R., Hatherill, M., Van Der Meeren, O., Ginsberg, A. M., Van Brakel, E., Salaun, B., Scriba, T. J., Akite, E. J., Ayles, H. M., Bollaerts, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1909953 · Cited by 605
Self-citationThe role of vaccines in combatting antimicrobial resistance
Micoli, F., Bagnoli, F., Rappuoli, R., & Serruto, D. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-00506-3 · Cited by 500
Building a tuberculosis-free world: The Lancet Commission on tuberculosis
Reid, M. J. A., Arinaminpathy, N., Bloom, A., Bloom, B. R., Boehme, C., Chaisson, R., Chin, D. P., Churchyard, G., Cox, H., Ditiu, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30024-8 · Cited by 361
Metadata
- Authors
- Van Der Meeren, O., Hatherill, M., Nduba, V., Wilkinson, R. J., Muyoyeta, M., Van Brakel, E., Ayles, H. M., Henostroza, G., Thienemann, F., Scriba, T. J., Diacon, A., Blatner, G. L., Demoitié, M.-A., Tameris, M., Malahleha, M., Innes, J. C., Hellström, E., Martinson, N., Singh, T., Akite, E. J., Khatoon Azam, A., Bollaerts, A., Ginsberg, A. M., Evans, T. G., Gillard, P., & Tait, D. R.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-10-25
- Volume
- 379
- Issue
- 17
- Pages
- 1621-1634
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2894391687
- Cited by
- 413
- References
- 31
- FWCI
- 39.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase 2b Controlled Trial of M72/AS01 E Vaccine to Prevent Tuberculosis. https://app.cochat.ai/papers/10.1056/nejmoa1803484
- The paper
- Van Der Meeren, O., Hatherill, M., Nduba, V., Wilkinson, R. J., Muyoyeta, M., Van Brakel, E., Ayles, H. M., Henostroza, G., Thienemann, F., Scriba, T. J., Diacon, A., Blatner, G. L., Demoitié, M.-A., Tameris, M., Malahleha, M., Innes, J. C., Hellström, E., Martinson, N., Singh, T., . . . Tait, D. R. (2018). Phase 2b Controlled Trial of M72/AS01 E Vaccine to Prevent Tuberculosis. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1803484
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.